Every article, report, and earnings note where AMGN appears.
7 articles
Amgen’s portfolio is shifting toward faster-growing products like Repatha, EVENITY, and TEZSPIRE, but leverage and biosimilar erosion keep the stock in Hold territory. MariTide is the key medium-term catalyst, while Prolia and XGEVA remain the biggest drag.
Five big pharma stocks are ranked in a countdown, comparing specialty franchises, profitability, valuation, growth and earnings consistency for July 2026.
Kardigan is expected to list on NASDAQ on 2026-06-18, with shares priced at $14.00 to $16.00. The IPO centers on a clinical-stage cardiovascular pipeline and a balance sheet that still needs capital to keep advancing. Watch whether investors focus on the three lead programs or the company’s going-concern warning.
Investors still talk about obesity drugs like a category ETF, but the evidence now points to a leadership trade. Eli Lilly is widening the gap with stronger execution, better prescription momentum, and a more threatening pipeline just as Novo Nordisk faces pricing pressure and a weaker growth profile.
Seven dividend growth stocks ranked by investment quality — Amgen, AbbVie, and McDonald's all place, while the top two spots wait at the end of the countdown.
Seven biotech stocks ranked by investment quality — Regeneron, Vertex, and Axsome all make the list, with the top two spots saved for the countdown's finish.
Amgen Inc. (AMGN) drops after reporting first-quarter 2026 results, even though the company beat Wall Street on earnings and revenue. Investors appear focused on valuation, growth quality, and whether the quarter was strong enough to justify the stock’s premium.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate AMGN ReportCancel anytime